< Back to previous page

Project

Unravelling the mechanism of single time vaccination strategy (SinTimVaS) (R-12649)

In this project, a new vaccination strategy is developed termed Single time vaccination strategy (SinTimVaS). This strategy consists of a single application of two simultaneous primes, one by the mucosal and another by parenteral way. This novel approach aims to increase vaccination coverage, reduce vaccination time and vaccination cost, and simultaneously induces specific IgA (mucosal protector) and IgG (systemic protection). While pilot experiments in mice for different antigen formulations were highly successful, the underlying mechanisms involved are largely unclear and will be studied in detail in this proposal. More specifically, the involvement of the spleen and the trafficking of antigen presenting cells, named dendritic cells, from the vaccination site to the secondary lymphoid organs will be investigated. In addition, the formation of cross reactive IgA antibodies is evaluated as a measure of protective mucosal immunity. This will provide insights into the SinTimVaS action mechanism and complement the current preclinical studies. These insights are essential to advance to vaccination clinical trials and will explain the superiority of nasal over the other mucosal routes with the induction of cross-reactive IgA.
Date:21 Feb 2022 →  31 Dec 2022
Keywords:IMMUNE THERAPY
Disciplines:Autoimmunity
Project type:Collaboration project